SELLAS Life Sciences Group, Inc. (SLS)
SELLAS develops cancer immunotherapy and targeted drug candidates for blood cancers and solid tumors. It last closed at $13.66 on Nov 20, down 8.08% on the day. The next earnings report for SLS is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, SLS reported EPS of -$0.05 on revenue of $0. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months SLS insiders bought $0 of stock on the open market and sold $717K, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From SLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Technical AnalysisPrices may be delayed
The stock is 23% above its 20 day and 18% above its 50 day average. It is 34% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot S1 at $12.97, and the nearest resistance the swing high (Jul 15) at $13.73.
| RSI (14) | 56.48 | Middle of its range | Neutral |
| MACD | 0.87 | Above its signal line | Bullish |
| Stochastic | 47.0 | Middle of its range | Neutral |
| ADX (14) | 33.3 | Trending up | |
| Williams %R | -63.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 81.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +62.2% | Change over 10 sessions | Bullish |
| ATR (14) | $2.36 | Typical daily range, 17.3% of price |
| RSI (14) | 59.02 | Middle of its range | Neutral |
| MACD | 0.56 | Below its signal line | Bearish |
| Stochastic | 20.1 | Middle of its range | Neutral |
| ADX (14) | 37.2 | Trending up | |
| Williams %R | -63.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 167.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +18.3% | Change over 10 sessions | Bullish |
| ATR (14) | $3.16 | Typical daily range, 23.1% of price |
What happened before
See how SLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in SLS in the last 90 days.
SLS Institutional Ownership
Full report →- ▲141 buying vs 61 selling
- ▼Held by funds -1.0 pts
- ▲Funds holding +25
- ▼Superinvestors: 0 added, 1 cut
- ▲Put/call 4.45 to 1.67
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 219 | 194 | +12.9% |
| In funds' top 10 | 0 | 2 | −100.0% |
| Held by funds | 35.4% | 36.4% | −1.0 pts |
| New / increased | 47 / 94 | 59 / 78 | +2.9% |
| Reduced / sold out | 38 / 23 | 26 / 28 | +13.0% |
| Put/call ratio | 1.67 | 4.45 | −62.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
SLS Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 18 | Angelos M. StergiouPresident and CEO | Sale | 26,606 | $19.18 | $510K |
| Nov 18 | Dragan CicicSVP, Chief Development Officer | Sale | 6,933 | $19.18 | $133K |
| Nov 18 | John Thomas BurnsCFO | Sale | 3,831 | $19.18 | $73K |
| Nov 19, 2025 | Katherine Bach KalinDirector | Buy | 63,400 | $1.59 | $101K |
| Jun 12, 2025 | Nostrand Robert L VanDirector | Buy | 10,000 | $1.48 | $15K |
| May 30, 2025 | Jane WasmanDirector | Buy | 20,000 | $1.69 | $34K |
From SEC Form 4 filings by SLS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLS is in one of them and how their past SLS trades turned out.
SLS News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SLS in an article yet. Here's the latest on the wider market.
- SELLAS Life Sciences Announces Pricing of $150.0
- Sellas Life Sciences Scores A Big Win: Here's What We Know (And What We Don't) (Rating Upgrade)
- Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
About SELLAS Life Sciences Group
SELLAS is a clinical stage biopharmaceutical company based in New York that develops treatments for cancer. Its lead candidate, galinpepimut-S, is an immunotherapy that targets the WT1 protein, which is found in many types of cancer, including blood cancers such as acute myeloid leukemia. The company is also developing tambiciclib, a small molecule drug that inhibits CDK9, for patients with blood and solid cancers. Both candidates are in clinical trials.
- Headquarters
- New York, NY
- Founded
- 2006
- Website
- galenabiopharma.com ↗
